BioRestorative Therapies Inc
$ 0.35
-6.25%
12 Jun - close price
- Market Cap 9,579,800 USD
- Current Price $ 0.35
- High / Low $ 0.38 / 0.35
- Stock P/E N/A
- Book Value 0.12
- EPS -1.06
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.19 %
- ROE -2.41 %
- 52 Week High 1.89
- 52 Week Low 0.16
About
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols that primarily involve adult stem cells. The company is headquartered in Melville, New York.
Analyst Target Price
$8.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-12 | 2025-08-12 | 2025-05-14 | 2025-03-27 | 2024-11-12 | 2024-08-13 | 2024-06-11 | 2024-03-29 | 2023-11-13 | 2023-08-11 |
| Reported EPS | -0.12 | -0.32 | -0.33 | -0.3 | -0.64 | -0.375 | -0.0068 | -0.5 | -0.33 | -0.57 | -0.65 | -0.77 |
| Estimated EPS | -0.24 | -0.34 | -0.38 | -0.38 | -0.34 | -0.5533 | -0.43 | -0.56 | -0.52 | -0.69 | -0.68 | -1.19 |
| Surprise | 0.12 | 0.02 | 0.05 | 0.08 | -0.3 | 0.1783 | 0.4232 | 0.06 | 0.19 | 0.12 | 0.03 | 0.42 |
| Surprise Percentage | 50% | 5.8824% | 13.1579% | 21.0526% | -88.2353% | 32.2248% | 98.4186% | 10.7143% | 36.5385% | 17.3913% | 4.4118% | 35.2941% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BRTX
2026-05-31 09:09:35
BioRestorative Therapies, Inc. has appointed Lance Alstodt as Chairman, CEO, and President under a new three-year employment agreement effective May 27, 2026. The agreement includes a base salary of $600,000, eligibility for a 50% annual bonus, and significant severance provisions, such as two times the combined salary and maximum bonus, two years of COBRA, and accelerated equity vesting upon termination without cause or resignation for good reason. Strong non-compete and non-solicit clauses are also in place for one year post-termination, with potential shareholder impact stemming from the generous severance terms affecting company financials during M&A or executive turnover.
2026-05-30 07:39:17
BioRestorative Therapies has extended the employment agreements for its President, Chief Executive Officer, and Chairman of the Board, Lance Alstodt, and its Chief Financial Officer, Robert Kristal. Both agreements are effective through May 27, 2029, with their current salaries remaining unchanged at $600,000 for Alstodt and $350,000 for Kristal. The filings indicate no other changes to their roles or board positions.
2026-05-29 20:39:17
BioRestorative Therapies, Inc. (BRTX) has significantly increased its authorized common shares from 75 million to 1.5 billion, following stockholder approval. The company also signed new three-year employment agreements with CEO Lance Alstodt and CFO Robert Kristal, outlining their salaries, bonus opportunities, and severance protections. These changes provide the company with greater flexibility for future equity issuance and secure executive leadership, though they highlight a potential for significant stock dilution and substantial executive protection terms.
2026-05-29 19:39:36
This article provides details on BioRestorative Therapies Inc.'s stock performance over a 52-week period, specifically focusing on its 52-week high, low, and current price. It also covers analyst projections for stock price over the next year and the company's valuation metrics.
2026-05-28 07:39:17
BioRestorative Therapies Inc. (BRTX) shares surged over 53% in premarket trading after activist hedge fund Kaos Capital disclosed a 4.9% stake. Kaos Capital is seeking an immediate meeting with the board to discuss strategic alternatives, suggesting the company explore a comprehensive strategic review and consider pivoting into artificial intelligence opportunities. The hedge fund believes shareholders are not gaining meaningful value from the existing business and aims to work constructively to enhance value.
2026-05-27 12:39:23
BioRestorative Therapies Inc (BRTX) shares surged over 53% in premarket trading after activist hedge fund Kaos Capital disclosed a 4.9% stake. Kaos Capital believes the company should explore strategic alternatives, including a potential pivot into artificial intelligence, to unlock shareholder value. The hedge fund aims to meet with the board to discuss these opportunities.
